Previous Article | Next Article 
Journal of Virology, September 2001, p. 7904-7912, Vol. 75, No. 17
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.17.7904-7912.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Posttranslational Processing of Infected Cell
Proteins 0 and 4 of Herpes Simplex Virus 1 Is Sequential and
Reflects the Subcellular Compartment in Which the Proteins
Localize
Sunil J.
Advani,1,2
Ryan
Hagglund,1
Ralph R.
Weichselbaum,2 and
Bernard
Roizman1,*
The Marjorie B. Kovler Viral Oncology
Laboratories1 and Department of
Radiation and Cellular Oncology,2 The
University of Chicago, Chicago, Illinois 60637
Received 21 March 2001/Accepted 18 May 2001
 |
ABSTRACT |
The herpes simplex virus 1 (HSV-1) infected cell proteins 0 and 4 (ICP0 and ICP4) are multifunctional proteins extensively posttranscriptionally processed by both cellular and viral enzymes. We
examined by two-dimensional separations the posttranslational forms of
ICP0 and ICP4 in HEp-2 cells and in human embryonic lung (HEL)
fibroblasts infected with wild-type virus, mutant R325, lacking the
sequences encoding the US1.5 protein and the overlapping carboxyl-terminal domain of ICP22, or R7914, in which the aspartic acid
199 of ICP0 was replaced by alanine. We report the following (i) Both
ICP0 and ICP4 were sequentially posttranslationally modified at least
until 12 h after infection. In HEL fibroblasts, the processing of
ICP0 shifted from A+B forms at 4 h to D+G forms at 8 h and finally to G, E, and F forms at 12 h. The ICP4 progression was from the A' form noted at 2 h to B' and C' forms noted at 4 h to the additional D' and E' forms noted at 12 h. The progression tended to be toward more highly charged forms of the proteins. (ii)
Although the overall patterns were similar, the mobility of proteins
made in HEp-2 cells differed from those made in HEL fibroblasts. (iii)
The processing of ICP0 forms E and F was blocked in HEL fibroblasts
infected with R325 or with wild-type virus and treated with
roscovitine, a specific inhibitor of cell cycle-dependent kinases cdc2,
cdk2, and cdk5. R325-infected HEp-2 cells lacked the D' form of ICP4,
and roscovitine blocked the appearance of the most highly charged E'
form of ICP4. (iv) A characteristic of ICP0 is that it is translocated
into the cytoplasm of HEL fibroblasts between 5 and 9 h after
infection. Addition of MG132 to the cultures late in infection resulted
in rapid relocation of cytoplasmic ICP0 back into the nucleus. Exposure
of HEL fibroblasts to MG132 late in infection resulted in the
disappearance of the highly charged ICP0 G isoform. The G form of ICP0
was also absent in cells infected with R7914 mutant. In cells infected
with this mutant, ICP0 is not translocated to the cytoplasm. (v) Last,
cdc2 was active in infected cells, and this activity was inhibited by
roscovitine. In contrast, the activity of cdk2 exhibited by immunoprecipitated protein was reduced and resistant to roscovitine and
may represent a contaminating kinase activity. We conclude from these
results that the ICP0 G isoform is the cytoplasmic form, that it may be
phosphorylated by cdc2, consistent with evidence published earlier
(S. J., Advani, R. R. Weichselbaum, and B. Roizman, Proc.
Natl. Acad. Sci. USA 96:10996-11001, 2000), and that the processing is reversed upon relocation of the G isoform from the cytoplasm into the nucleus. The processing of ICP4 is also affected by
R325 and roscovitine. The latter result suggests that ICP4 may also be
a substrate of cdc2 late in infection. Last, additional modifications
are superimposed by cell-type-specific enzymes.
 |
INTRODUCTION |
Herpes simplex virus 1 (HSV-1) gene
expression is sequentially ordered in a cascade fashion
(33). The
genes are the first set of genes to be
transcribed. The products, the infected cell polypeptide 0 (ICP0),
ICP4, ICP22/US 1.5, ICP27, and ICP47, play a prominent role
in regulating viral replication and the environment of the infected
cell to ensure an orderly expression of viral genes and evasion of
cellular responses to infection. To attain these objectives, the
proteins with the possible exception of ICP47 express multiple
functions. Related to the multifunctionality of these proteins is the
extensive posttranslational processing to which they are subjected
throughout the replicative cycle of the virus. The posttranslational
processing includes poly(ADP-ribosyl)ation (ICP4), nucleotidylylation
by casein kinase II (ICP0, ICP4, ICP22, and ICP27), and phosphorylation
by both viral and cellular kinases (4, 5, 25, 26, 31, 41-43,
45). While earlier reports have focused on the viral kinases
(US3 and UL13) and certain cellular kinases
(protein kinases A and C and casein kinase II) and their role in
modifications of HSV-1
proteins, recent reports have suggested a
possible involvement of JNK1 and of the cyclin-dependent kinase cdc2 in
the regulation of viral gene expression (2, 21). The focus
of this report is on posttranslational modifications of two
proteins, ICP4 and ICP0.
ICP4, a DNA-binding nuclear phosphoprotein, is the major regulatory
protein encoded by HSV-1. The effect of its many and not fully
characterized functions is to regulate viral gene expression both
positively and negatively. Negative regulation is achieved by binding
to high-affinity response elements situated at the transcription
initiation sites (18, 33), whereas positive regulation of
transcription is associated with low-affinity, nonconsensus sites
scattered throughout the genome (23, 24). The protein contains consensus phosphorylation sites for cellular protein kinases A
and C and casein kinase II (42, 43). The state of phosphorylation of ICP4 has been reported to differentially regulate its ability to bind to HSV-1 viral promoters of different kinetic gene
classes (28). Whereas unphosphorylated ICP4 can retain its
ability to bind to
promoter elements, phosphorylation of ICP4 is
needed to bind to promoter elements of
and
genes.
Early in infection, ICP0 localizes to the nucleus. In some cells, and
particularly in primary human embryonic lung (HEL) fibroblasts, ICP0 is
translocated to the cytoplasm between 5 and 9 h after infection
(14, 40). The apparent phenotype of ICP0 is that of a
promiscuous transactivator. Biochemical studies indicate that ICP0
interacts with several viral and cellular proteins (14-16, 39,
44). Consistent with the presence of a ring finger structure, ICP0 is involved in the ubiquitin-proteasomal degradation pathway (8-11, 29). In addition to the posttranslational
modifications described above, ICP0 is also phosphorylated by both
US3 and UL13 viral protein kinases (26,
31).
Both ICP0 and ICP4 form multiple bands on electrophoresis in denaturing
polyacrylamide gels. In early studies, each of these proteins has been
shown to form multiple spots on two-dimensional separations
(1). In order to relate the posttranslational
modifications of these two proteins to stages of viral replication and,
in the case of ICP0, to the translocation from nucleus to the
cytoplasm, we have used two-dimensional gel electrophoresis to discern
specific forms of ICP0 and ICP4 that accumulate during a 12-h time
course of infection. Two-dimensional gel electrophoresis analysis
allows resolution of differentially charged protein isoforms that
migrate at similar apparent molecular weights on one-dimensional
separations in denaturing polyacrylamide gels. Relevant to these
studies are the following observations.
(i) Cdc2 kinase activity increases in HSV-1-infected cell lysates
between 8 to 12 h after infection (2) even though its partners, cyclins A an B, are degraded and virtually undetectable at
that time after infection. Cdc2 is a proline-directed serine/threonine kinase normally active during the G2/M phase of the cell
cycle, and its consensus phosphorylation site has been defined as
(S/T)PX(K/H/R) (17, 20). This consensus phosphorylation
site is present in many HSV-1-encoded proteins (3). Of
particular interest are the
proteins ICP0 and ICP4, which contain
multiple potential cdc2 kinase phosphorylation sites. In HSV-1-infected
cells treated with roscovitine, an inhibitor of cdc2, cdk2, and cdk5,
viral replication and transcription are inhibited (13,
34-36).
(ii) The activity of cdc2 is regulated by both ICP22 and
UL13 (2). Inhibition of cellular cdc2 kinase
by overexpression of a dominant negative form results in diminished
accumulation of US11 (a
2 protein)
(3). ICP22 and UL13 expression are essential for wild-type-level expression of
2 genes (27,
32).
(iii) ICP0 binds to and stabilizes cyclin D3. A single amino acid
substitution (D199A) abolishes this function of ICP0. In addition, ICP0
of the D199A substitution mutant (R7914) is not translocated from the
nucleus to the cytoplasm, and the mutant virus exhibits reduced
replication in quiescent HEL fibroblasts and reduced neuroinvasiveness
in mice infected at a site peripheral to the central nervous system
(39). Published evidence suggests that the translocation
of ICP0 to the cytoplasmic compartment of HEL fibroblasts correlates
with binding of cyclin D3 and involvement of proteasomal components.
The latter association is based on the observation that proteasomal
degradation inhibitor MG132 administered late in infection causes the
relocation of ICP0 from the cytoplasm to the nucleus (19).
The central hypotheses tested in this study are that the
posttranslational modifications of ICP4 and ICP0 are sequential and that they are associated with specific locations of the proteins within
cellular compartments. We report that this is indeed the case.
 |
MATERIALS AND METHODS |
Cells and viruses.
HEp-2 cells were obtained from the
American Type Culture Collection and maintained in Dulbecco's modified
Eagle's medium supplemented with 10% serum. HEL fibroblasts were
initially obtained from Aviron (Mountain View, Calif.) and maintained
in 10% newborn calf serum. HSV-1(F) is the prototype wild-type HSV-1
strain used in our laboratory (7). R325, lacking the
carboxyl-terminal domain of ICP22, and R7914, in which the aspartic
acid 199 of ICP0 was replaced by alanine, have been previously
described (30, 39).
Cell Infection.
HEp-2 cells were harvested and reseeded on
25-cm2 flasks. Cells were allowed to adhere for 1 h,
after which unattached cells were aspirated. The adhered cells were
exposed to 2 × 107 PFU of appropriate virus in 1 ml
of 199V (mixture 199 supplemented with 1% calf serum) on a rotary
shaker at 37°C. After 2 h, the inoculum was replaced with 5 ml
of fresh Dulbecco's Modified Eagle's medium supplemented with 10%
calf serum. Flasks were incubated at 37°C until the cells were
harvested. HEL fibroblasts grown to 100% confluency in
150-cm2 flasks were maintained for 1 week prior to
infection. They were exposed to virus in 199V for 2 h and then
maintained in the spent growth medium. The proteasome inhibitor, MG132,
was added to infected HEL fibroblast cultures at 8 h after
infection at a final concentration of 0.5 mg/ml (Calbiochem).
Two-dimensional gel electrophoresis.
Cells were harvested
for two-dimensional electrophoresis at time points indicated in Results
as follows. The medium was aspirated from flasks, and the cells were
rinsed with phosphate-buffered saline, scraped into 5 ml of
phosphate-buffered saline, pelleted by centrifugation, and suspended in
80 µl of lysis solution (8 M urea, 4% CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, 40 mM Tris base). The extract was kept on ice for 1 h and sonicated, and the insoluble material was pelleted by centrifugation. The soluble
fraction was transferred to a new tube, 170 µl of rehydration stock
solution (8 M urea, 2% CHAPS, 20 mM dithiothreitol [DTT], bromophenol blue) was added to the sample for a total volume of 250 µl, and 0.5% of pH 3 to 10 IPG buffer (Amersham-Pharmacia Biotech)
was added. First-dimension isoelectric focusing was done in an IGPhor
electrophoresis unit (Amersham-Pharmacia Biotech). Immobilized pH 3 to
10 linear gradient strips (13 cm in length) were rehydrated with the
sample solution for 12 h and then subjected to the following
procedures: 500 V for 1 h, 1,000 V for 1 h, and 8,000 V for
2 h, for a total of 17,500 V-h. The immobilized strips were then
equilibrated in 10 ml of sodium dodecyl sulfate (SDS) buffer (50 mM
Tris [pH 8.8], 6 M urea, 30% glycerol, 2% SDS, 70 mM DTT,
bromophenol blue) for 15 min. The immobilized strips were then overlaid
onto 6% bisacrylamide gels and sealed with 0.5% agarose in SDS-gel
running buffer containing bromophenol blue. Molecular weight markers
were placed adjacent to the pH 10 side of the immobilized strips. Gels
were subjected to 20 mA for the first hour followed by 30 mA. The
electrophoretically separated proteins in the second dimension were
then transferred to a nitrocellulose sheet and probed with antibodies
to ICP0 and ICP4 as described elsewhere (1).
32P labeling and roscovitine treatment.
HEp-2
cells were seeded and infected as above. At 5 h after infection, the
cells were incubated in phosphate-depleted Eagle's minimal essential
medium (EMEM) containing dimethyl sulfoxide (DMSO) or 100 µM
roscovitine (Calbiotech) in DMSO. The cells were labeled from 6 to
10 h after infection with 200 µCi (per 25-cm2 flask)
of 32P-orthophosphate (Amersham) in EMEM (1% serum)
containing DMSO or roscovitine and DMSO and harvested as above for
two-dimensional gel electrophoresis. After transfer to nitrocellulose,
membranes were analyzed with the aid of a Molecular Dynamics Storm 860 PhosphorImager and autoradiography and then immunoblotted with
antibodies to ICP0 and ICP4.
In vitro kinase assays.
HEp-2 cells were mock or HSV-1(F)
infected as above. Five hours postinfection, roscovitine (10 or 100 µM) or an equivalent volume of vehicle (DMSO) was added to the cells.
Cells were harvested 12 h after infection in high-salt lysis
buffer (20 mM Tris [pH 8.0], 1 mM EDTA, 0.5% NP-40, 400 mM NaCl, 2 mM DTT, 0.1 mM sodium orthovanadate, 10 mM NaF 100 µg each of
phenylmethylsulfonyl fluoride and tolylsulfonyl phenylalanyl
chloromethyl ketone per ml, 2 µg each of aprotonin and leupeptin per
ml). Equivalent protein concentrations of cell lysates were initially
precleared with preimmune sera followed by the addition of 50 µl of a
50% protein A slurry (Sigma). Cdk2 and cdc2 were then
immunoprecipitated with their specific antibodies and collected by
addition of 20 µl of a 50% protein A slurry. The immunoprecipitates
were then washed twice in high-salt lysis buffer, twice in low-salt
lysis buffer (20 mM Tris [pH 8.0], 1 mM EDTA, 0.5% NP-40, 1 mM NaCl,
2 mM DTT), and twice in incomplete kinase buffer (50 mM Tris [pH
7.4], 10 mM MgCl2, 5 mM DTT). In vitro kinase reactions
were carried out using histone H1 (Boehringer Mannheim) as the
substrate. Forty microliters of complete kinase buffer (50 mM Tris [pH
7.4], 10 mM MgCl2, 5 mM DTT, 10 µM ATP, 20 µCi of
[
-32P]ATP, 2 µg of histone H1) was added to
immunoprecipitated cdk2 or cdc2. The samples were reacted at 30°C for
20 min, and the reaction was terminated by the addition of SDS-gel
loading buffer (2% SDS, 5%
-mercaptoethanol, 50 mM Tris [pH
6.8], 2.75% sucrose) and heated to 95°C for 5 min. The samples were
resolved by polyacrylamide gel electrophoresis, transferred to a
nitrocellulose sheet, and analyzed by autoradiography. Quantification
of 32P phosphorylation of the histone H1 was done with the
aid of a PhosphorImager (Storm 860; Molecular Dynamics).
 |
RESULTS |
ICP0 and ICP4 are progressively modified over the course of HSV-1
infection.
The purpose of these experiments was to determine the
sequence of accumulation of modified forms of ICP0 and ICP4 in the
course of HSV-1 infection. Infected cells were harvested at 2, 4, 8, and 12 h after infection for HEp-2 cells and at 4, 8, and 12 h after infection of HEL fibroblasts. The cell lysates were then subjected to two-dimensional electrophoresis as described in Materials and Methods. The two-dimensionally separated polypeptides were reacted
with antibodies to ICP0 and ICP4. Over the course of the first 12 h of infection, both ICP0 and ICP4 were continuously posttranslationally modified. Figure 1
shows the forms of ICP0 that were detected in HEp-2 cells. At 2 h
after infection, two sets of species, designated A and B, were present.
At 4 h after infection, A and B were replaced by three new
species, C, D, and E. By 8 h after infection, species C
disappeared, whereas species D and E accumulated in higher quantities.
Finally at 12 h after infection, a reduction in species D occurred
and there was a trend toward more negatively charged forms (E and F).

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 1.
Immunoblots of ICP0 in two-dimensionally separated
HSV-1- or R325-infected HEp-2 cell lysates. Infected cells were
harvested at the indicated times postinfection. Time zero was defined
as the time the viral inoculum was added to the cells. Lysates were
first separated by charge on linear pH 3 to 10 gradients and then
separated by size on 6% bisacrylamide gels as described in Materials
and Methods. Blots were reacted with a monoclonal antibody to ICP0. The
major isoforms that accumulated are given letter designations.
|
|
The patterns of posttranslational modifications of ICP0 processing in
infected HEL fibroblasts are shown in Fig.
2. At 4 h
after HSV-1 infection, the
prominent species of ICP0 present were
designated A and B. By 8 h
after infection, these forms were replaced
by a faster, less negatively
charged D form and a more abundant,
slower-migrating, more negatively
charged G species of ICP0. By
12 h after infection, the three
major species of ICP0 were E and
F in addition to the G form. The C
isoform of ICP0 was not detected
in lysates of infected HEL
fibroblasts, suggesting that the accumulation
of this isoform is cell
type dependent.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoblots of ICP0 in two-dimensionally separated
HSV-1-infected HEL fibroblast cell lysates. HSV-1-infected cells were
harvested at 4, 8, and 12 h postinfection (P.I.). In addition
cells were also treated with MG132 or roscovitine. MG132 was given to
HSV-1-infected cells 8 h after infection and harvested at 12 h. Roscovitine was added to HSV-1-infected cells at 5 h after
infection, and cells were harvested at 12 h postinfection.
Immunoblots were reacted with ICPO monoclonal antibody.
|
|
Figure
3 shows the pattern of ICP4 forms
that accumulate over the first 12 h after infection in HEp-2
cells. At 2 h after
infection, we identified a species designated
A'. At 4 h after
infection, ICP4 was present as a major species
(B') with a less
negative charge and a more highly negatively charged,
C' species.
By 8 h after infection, the majority of ICP4 migrated
around C'.
Finally, at 12 h after infection, as was the case for
ICP0, the
accumulating ICP4 formed two new, more highly negatively
charged
species designated D' and E' in addition to the preexisting C'
species.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 3.
Immunoblots of ICP4 in two-dimensionally separated
HSV-1-+ and R325-infected HEp-2 cell lysates. Immunoblots were prepared
and reacted with the anti-ICP4 monoclonal antibody as described in the
legend to Fig. 1.
|
|
Phosphorylation of ICP0 and ICP4 is sensitive to roscovitine.
Roscovitine has been reported to be a relatively specific inhibitor of
certain cyclin-dependent kinases (cdk2, cdk5, and cdc2) (22). In addition, roscovitine was reported to adversely
affect HSV-1 transcription and overall replication (13,
34-36). Elsewhere, this laboratory reported that cdc2 kinase
activity is upregulated in HSV-1-infected cells between 8 and 12 h
after infection (2). Also, ICP0 and ICP4 both contain
multiple consensus phosphorylation sites for cdc2, and a glutathione
S-transferase fusion protein encoding ICP0 exon II was
phosphorylated by cdc2 kinase (3).
To determine whether roscovitine blocked the accumulation of any of the
isoforms of ICP0 or ICP4, HEp-2 cells were infected
with HSV-1(F). At
5 h after infection, the cells were treated
with 100 µM
roscovitine or an equivalent volume of DMSO (0.1%)
in
phosphate-depleted EMEM. At 6 h after infection, the medium
was
supplemented with
32P-orthophosphate, and the exposure to
roscovitine or DMSO was
continued until 10 h after infection.
Cells were then harvested
and lysed, and whole-cell lysates were
subjected to two-dimensional
gel electrophoresis. Autoradiograms and
immunoblots for ICP0 and
ICP4 were done. The results are shown in
Fig.
4 and
5.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 4.
Immunoblots (A and C) and corresponding autoradiograms
(B and D) of ICPO in two-dimensionally separated
32P-orthophosphate-labeled HSV-1-infected HEp-2 cell
lysates to determine roscovitine-sensitive ICP0 phosphorylation.
HSV-1-infected HEp-2 cells were treated with roscovitine or an
equivalent volume of DMSO at 5 h after infection in phosphate-free
medium. Infected cells were labeled with 32P-orthophosphate
from 6 to 10 h postinfection in the presence of roscovitine. Cells
were harvested at 10 h postinfection, and whole-cell lysates were
subjected to two-dimensional electrophoresis. Membranes were developed
by autoradiography and immunoblotted with an ICP0 antibody. Isoform
designations are identical to those shown in Fig. 1.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
Immunoblots (A and C) and corresponding autoradiograms
(B and D) of ICP4 in two-dimensionally separated
32P-orthophosphate-labeled HSV-1-infected HEp-2 cell
lysates to determine roscovitine-sensitive ICP4 phosphorylation.
HSV-1-infected HEp-2 cells were treated with roscovitine or an
equivalent volume of DMSO at 5 h after infection in phosphate-free
medium. Infected cells were labeled with 32P-orthophosphate
from 6 to 10 h after infection in the presence of roscovitine.
Cells were harvested at 10 h postinfection, and whole-cell lysates
were subjected to two-dimensional electrophoresis. Membranes were
developed by autoradiography and immunoblotted with an ICP4 antibody.
Isoform designations are idential to those shown in Fig. 3.
|
|
At 10 h after infection, the lysates of cells exposed to DMSO
contained two isoforms of ICP0 corresponding to isoforms D and
E of
Fig.
1 that were readily apparent by their reactivity with
the
anti-ICP0 antibody (Fig.
1 and
4A). These forms corresponded
to
phosphoforms as determined by autoradiography of the same blot
(Fig.
4B). Exposure to roscovitine resulted in a decreased accumulation
of
the more negatively charged E species of ICP0 and greater accumulation
of the less negatively charged D isoform (Fig.
4A and C). The
results
of autoradiography of the two-dimensionally separated
polypeptides from
roscovitine-treated infected cell lysate yielded
concordant decreased
accumulation of the labeled E species compared
to that of DMSO-treated
controls (Fig.
4B and
D).
The same blots were also probed with antibody against ICP4. At 10 h after infection, three species of ICP4 corresponding to
the C', D',
and E' of Fig.
3 reacted with the anti-ICP4 antibody
(Fig.
3D and
5A).
All three forms were labeled with
32P-orthophosphate (Fig.
5B). Roscovitine had a similar effect on
the accumulation of specific
species of ICP4 phosphoproteins.
Roscovitine treatment resulted in the
loss of the most negatively
charged ICP4 species (E') (Fig.
5C). In
lysates of roscovitine-treated
cells, there was a greater accumulation
of less negatively charged
phosphorylated species (C' and D'). We
conclude from this experiment
that roscovitine blocked the accumulation
of specific, highly
negatively charged species of ICP0 (isoform E) and
ICP4 (isoform
E') in HEp-2 cells infected with wild-type virus. The
forms blocked
by roscovitine were those that accumulated in significant
amounts
at or after 8 h after
infection.
Specific forms of ICP0 in HEL fibroblasts were also sensitive to
roscovitine treatment (Fig.
2B, C, and E). In this instance
roscovitine
blocked the accumulation of the E and F species, which
normally
accumulated between 8 and 12 h after infection. Instead,
roscovitine-treated HEL fibroblasts accumulated the less negatively
charged D isoform of ICP0 at 12 h after infection that was present
in wild-type virus-infected cells at 8 h after infection. The
pattern of ICP0 accumulation at 12 h after 7 h of exposure to
roscovitine was similar to that observed at 8 h after infection,
suggesting that roscovitine blocked further processing of ICP0
in HEL
fibroblasts so that forms E and F of ICP0 could not
accumulate.
Exposure of HSV-1-infected cells to roscovitine inhibits cdc2 but
not the background activity associated with immunoprecipitated cdk2
kinase.
As stated above, roscovitine is a relatively specific
inhibitor of cyclin-dependent kinases cdc2, cdk2, and cdk5
(22). To determine if cdk2 or cdc2 is a target of
roscovitine in HSV-1-infected cells, the following experiment was done.
Mock- or HSV-1-infected cells were exposed to either roscovitine (10 and 100 µM) or DMSO at 5 h after infection. Cdk2 and cdc2 kinase
activities were then measured at 12 h after infection. The results
are shown in Fig. 6. Mock-infected cells
had elevated levels of cdk2 kinase activity, with significantly lower
levels of cdc2 activity. In mock-infected cells, a dose response was
seen upon addition of roscovitine when histone H1 was used as a
substrate. At 100 µM concentrations of roscovitine, both cdk2 and
cdc2 resulted in a 75% reduction in phosphorylation of histone H1. In
HSV-1-infected cells, cdk2 was not activated. Addition of up to 100 µM roscovitine resulted in only a 25% reduction in histone H1
phosphorylation by cdk2-immunoprecipitated samples from HSV-1-infected
lysates. Thus, the level of histone H1 phosphorylation by
immunoprecipitated cdk2 from lysates of mock-infected cells treated
with 100 µM roscovitine was comparable to cdk2 activity in
HSV-1-infected cell lysates with no roscovitine. These results argue
that cdk2 activity is shut down in HSV-1 infected cells and that the
phosphorylation of histone H1 observed in HSV-1 lysates is background
phosphorylation, consistent with the results previously reported for
cdk2 kinase activity in HSV-1 infected cells (6, 40). In
contrast, immunoprecipitated cdc2 kinase activity is greater in
HSV-1-infected cell lysates than in mock-infected cell lysates, as has
been previously reported (2). cdc2 kinase activity from
HSV-1-infected cell lysates shows a roscovitine dose-dependent
response. At 100 µM roscovitine, the cdc2 kinase activity from
HSV-1-infected cell lysates was reduced by 80% compared to 0 µM
roscovitine.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Autoradiograms of histone H1 phosphorylated by in vitro
kinase assays using immunoprecipitated cdk2 or cdc2 from HSV-1- or
mock-infected cells. HEp-2 cells were HSV-1 or mock infected; 5 h
after infection, the medium was replaced with medium containing 0, 10, or 100 µM roscovitine. Cells were harvested 12 h after
infection, and cdk2 or cdc2 was immunoprecipitated (IP) with antibodie
(Ab) as described in Materials and Methods. Kinase assays were done
using histone H1 as the substrate. Phosphorylated histone H1 was
quantitated by a PhosphorImager. Relative reduction in the
phosphorylation of histone H1 due to roscovitine was determined
relative to untreated samples.
|
|
We conclude from these studies that roscovitine at the dose used (100 µM) targets cdc2 kinase in HSV-1-infected cells. The
effect on cdk2
is inapparent since this cyclin-dependent kinase
is either inactive or
rendered insusceptible to inhibition by
roscovitine.
Involvement of
22/US1.5 in the accumulation of
specific forms of ICP0 and ICP4.
Earlier studies have shown that
in cells infected with the R325 mutant lacking the carboxyl-terminal
domain of ICP22 and also the domain encoding the overlapping
US1.5 open reading frame, the expression of
2 genes was reduced (30, 37). Activation of
cdc2 in HSV-1-infected cells is also dependent on ICP22, and overexpression of a dominant negative form of cdc2 resulted in the
decreased accumulation of US11, a
2 protein
(2, 3, 38). To examine the effects of
22 deletion virus
on ICP0 and ICP4 processing, two-dimensional electrophoresis was done
on lysates of HEp-2 cells harvested at 4 and 12 h after infection
with R325 deletion mutant. The results shown in Fig. 1 and 3 were as follows.
(i) As illustrated in Fig.
1, the electrophoretic mobility of ICP0 in
lysates of R325 mutant-infected HEp-2 cells harvested
at 4 h after
infection was similar to that of ICP0 harvested from
wild-type
virus-infected cells harvested at the same time after
infection. ICP0
present in lysates of cells harvested 12 h after
infection with
R325 mutant consisted primarily of the D isoform
and a small amount of
the E isoform. Absent were the highly negatively
charged F species
present in lysates of wild-type virus-infected
cells. The
electrophoretic mobility of ICP0 accumulated in R325
virus-infected
cells at 12 h after infection corresponded to that
of ICP0 in
wild-type virus-infected cells at 8 h after
infection.
(ii) As illustrated in Fig.
3, ICP4 present in HEp-2 cells harvested
4 h after infection with R325 mutant was primarily of
the C'
isoform, although we also detected trace amounts of the
B' isoform. In
contrast to ICP4 harvested from wild-type virus-infected
cells, the B'
species was absent (Fig.
3B and E). The posttranslational
modification
of ICP4 was arrested at this point since the protein
present in cells
harvested at 12 h after infection with R325 mutant
formed
primarily the C' species (Fig.
3E and F). Absent were the
highly
negatively charged D' and E' species which accumulated
in cells
harvested at 12 h after infection with wild-type virus
(Fig.
3D).
In HEL fibroblasts, R325 infection resulted in the accumulation of
species of ICP0 that resembled those present in infected
cells treated
with roscovitine (Fig.
2E and
7B). At
12 h after
infection, the G isoform of ICP0 was present in lysates
of both
wild-type virus- and R325 mutant-infected HEL fibroblasts (Fig.
7). However, form E was not observed in R325-infected cell lysates;
instead, a less negatively charged, D species was present. This
species
was also present in lysates of cells infected with wild-type
virus and
treated with roscovitine (Fig.
2E).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
Immunoblots of ICP0 in two-dimensionally separated
lysates of HSV-1- or R325-infected HEL fibroblasts. Cells were
harvested at 12 h after infection and separated by two-dimensional
electrophoresis. Immunoblots were reacted with ICP0 monoclonal
antibody. Isoform designations are the same as in Fig. 2.
|
|
The pattern of accumulation of the ICP0 isoforms in cells infected
with R7914 was similar to that of HEL fibroblasts infected with
wild-type virus and treated with MG132.
Studies reported elsewhere
have shown that in HSV-1(F)-infected HEL fibroblasts, ICP0 localized in
the nucleus early in infection and in the cytoplasmic compartment at
late times after infection (14, 40). Treatment of
HSV-1-infected HEL fibroblasts late in infection with the proteasome
inhibitor MG132 resulted in the relocation of ICP0 to the nucleus
(19). The goal of this set of studies was to determine if
differential subcellular localization of ICP0 was in part dependent on
its posttranslational modifications. To this end, two experiments were
done. HEL fibroblasts were infected with R7914 or HSV-1 and then
treated with MG132.
HEL fibroblasts infected with HSV-1 or R7914 were harvested 12 h
after infection. Two-dimensional gel electrophoresis revealed
that
whereas isoforms E and F were found in lysates from both
HSV-1- and
R7914-infected cells, the highly negatively charged
species (G) was
present only in HSV-1-infected cell lysates (Fig.
8). Treatment of HSV-1-infected HEL
fibroblasts with MG132 at
8 h after infection also resulted in the
loss of species G (Fig.
2D). MG132 had no appreciable effect on the
accumulation of E
and F forms of ICP0. These results suggest that the G
species
may represent cytoplasmic forms of ICP0 whereas the E and F
species
represent nuclear species of ICP0.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 8.
Immunoblots of ICP0 in two-dimensionally separated
lysates of HSV-1 or R7914 (alanine substituted for aspartic acid of
ICP0)-infected HEL fibroblasts. The cells were harvested at 12 h after
infection, lysed, and subjected to two-dimensional electrophoresis.
Immunoblots were reacted with anti ICP0 antibody. Isoform designations
are the same as in Fig. 2.
|
|
 |
DISCUSSION |
The fundamental hypothesis underlying these studies is that in the
case of multifunctional HSV-1 proteins, posttranslational modifications
determine the specific function performed by the protein at the
specific time or cellular compartment in which it is localized. ICP4
and ICP0, the two
regulatory proteins selected for this study, are
posttranslationally modified by multiple viral and cellular enzymes and
play a role in viral replication throughout the viral replicative
cycle. In this report we show that consistent with this hypothesis,
both ICP4 and ICP0 are sequentially modified throughout at least
12 h after infection and that at least some of the modifications
reflect the action of specific enzymes or correlate with localization
in specific cellular compartments. The salient features of the data are
schematically depicted in Fig. 9 and may
be summarized as follows.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 9.
Schematic representation of ICP0 and ICP4 isoforms
observed after two-dimensional separation of lysates of HSV-1-infected
HEL fibroblasts. (A) Absence of specific isoforms from lysates of HEL
fibroblasts infected with HSV-1 mutants or with wild-type virus and
treated with roscovitine. Isoforms E and F failed to accumulate in
lysates of R325-infected or roscovitine-treated, HSV-1-infected cells.
These isoforms are putative nuclear forms, and their processing is
dependent on cdc2 kinase. HEL fibroblasts infected with R7914 or
wild-type virus and treated with MG132 failed to accumulate the G
isoform, and this isoform appears to be associated with ICP0
translocated into the cytoplasm. (B) Isoforms D' and E' of ICP4 failed
to accumulate in HEL fibroblasts infected with R325 mutant. The most
negatively charged, E' isoform of ICP4 was not detected in significant
amounts in cells infected with wild-type virus and treated with
roscovitine. The accumulation of the ICP4 isoform E' may also be
dependent on cdc2 kinase.
|
|
(i) Over the course of infection, ICP0 and ICP4 are sequentially
processed. The general trend was the accumulation of more negatively
charged forms of both ICP0 and ICP4 as infection proceeded. This was
observed in both infected HEp-2 cells and HEL fibroblasts. Earlier
reports indicated that hyperphosphorylated forms of ICP4 are necessary
to bind to promoter elements on
and
genes (28). Increasing accumulation of negatively charged forms of ICP0 and ICP4 is
consistent with the requirements for post-
gene expression and with
the evidence that ICP4 is required throughout viral replication.
(ii) We have previously shown that cdc2 kinase activity is enhanced in
HSV-1-infected cells (2). A central question related to
that observation is why cdc2 was activated so late in the replicative cycle. This question was solved to some extent in studies with an
inactive, dominant negative mutant form of cdc2 (3, 38). Cells infected with wild-type virus and transfected with cdc2 dominant
negative construct expressed representative
,
, and
1 genes but failed to accumulate significant amounts of
US11, a representative
2 protein. Optimal
expression of
2 genes is in part dependent on ICP22 and
UL13 (27, 32). A cascade can be envisioned
involving UL13 and ICP22 activating cdc2, resulting in
enhanced
2 gene expression. The data in the present
study add further weight to such a scenario. Forms of ICP0 and ICP4 that accumulated between 8 and 12 h after HSV-1 infection were sensitive to both roscovitine as well as infection by the recombinant R325, which lacks the domain encoding the US1.5 protein and
the coterminal carboxyl-terminal domain of ICP22.
Roscovitine treatment of HSV-1-infected cells resulted in a loss of
specific phospholabeled forms of both ICP0 and ICP4 (Fig. 4, 5, and 9).
The forms of ICP0 and ICP4 phospholabeled in the presence of
roscovitine may reflect the effects of other kinases that phosphorylate
ICP0 and ICP4. Roscovitine is a relatively selective inhibitor of cdk2,
cdc2, and cdk5 (22). The effects of roscovitine on HSV-1
replication and gene transcription have been previously reported
(13, 34-36). The major effect of roscovitine in
HSV-1-infected cells was on cdc2; the cdk2-associated activity, the
other target of roscovitine, either represented background kinase
activity not associated with this enzyme or was shielded from the
inhibitory effects of roscovitine.
The absence of the carboxyl-terminal domain of ICP22 and the
corresponding absence of US1.5 protein had a drastic effect
on the posttranslational modification of ICP0 and ICP4. In contrast to
wild-type virus-infected cells, cells infected with the R325 mutant
virus accumulated at 12 h after infection the same forms of ICP0
and ICP4 as those that were present at 4 h after infection with
either wild-type or mutant virus (Fig. 9). The missing forms were those
that were more negatively charged and that were sensitive to
roscovitine. These observations are consistent with the data showing
that activation of cdc2 requires intact
22/US1.5 gene products. In light of the observation reported earlier that exon II of
ICP0 is a substrate for cdc2, it is likely that ICP0 and ICP4 serve as
bona fide in vivo substrates for cdc2. However, it appears that ICP22
may influence the activity of other kinases as well.
(iii) The results presented in this study indicate a correlation
between the extent of posttranslational modifications of ICP0 and its
localization in the infected cell. In HEL fibroblasts, ICP0 initially
localizes to the nucleus (14, 40) and later, between 5 and
9 h after infection, is translocated to the cytoplasm. One
mechanism for altering subcellular localization of proteins is through
posttranslational processing (12). In lysates of HSV-1-infected HEL fibroblasts, a novel, highly negative charged form
of ICP0 appeared between 4 and 8 h after infection (isoform G
[Fig. 2]). Two lines of evidence support that this highly negatively charged form of ICP0 in HEL cells correlates with cytoplasmic localization. First, ICP0 encoded by the recombinant virus R7914 accumulates in the nucleus and is not translocated to the cytoplasm (40). In HEL fibroblasts infected with the R7914 mutant,
the highly negatively charged G form did not accumulate (Fig. 8). Second, in cells infected with wild-type virus and treated with MG132
at late times after infection, ICP0 is translocated from the cytoplasm
to the nucleus (again), the D form of ICP0 was not detected in HEL
fibroblasts infected with HSV-1(F) and treated with MG132 late in
infection (Fig. 2C and D). The latter observation is particularly
significant since it suggests that the posttranslational modification
associated with the G form of ICP0 is reversible and specifically
associated with the cytoplasmic localization of the protein. Whereas
the G form of ICP0 is cytoplasmic, the E and F isoforms may represent
nuclear species.
The G form of ICP0 was present in cells infected with R325 and in cells
infected with wild-type virus and exposed to inhibitory concentrations
of roscovitine. These results indicate that neither ICP22/US1.5 protein or cdc2 is required for cytoplasmic
localization of ICP0.
(iv) Finally, we observed differences in the electrophoretic mobility
of ICP0 and ICP4 derived from HEp-2 cells or HEL fibroblasts infected
with wild-type or mutant virus. A notable example of these differences
is the absence of the C isoform of ICP0 in lysates of wild-type
virus-infected HEL fibroblasts. The differences most likely reflect
posttranslational modifications of the viral proteins effected by
enzymes specific for each cell type. The significance of these
observations stems from the observation that the level of accumulation
of many HSV-1 proteins varies depending on the cell line. In this
laboratory at least, several cell lines are screened to determine the
level of accumulation of specific proteins. The significant aspect
relevant to this study are deletion mutants in
22/US1.5.
The recombinant virus R325, for example, replicates almost as well as
wild-type virus in HEp-2 cells but at much reduced levels in primary
human cell lines or in cell lines of rodent or rabbit derivation
(37). Cell infected with this mutant underproduce a subset
of
2 proteins; the magnitude of the effect is cell type dependent (27, 37). It is conceivable that cell type
specificity reflects the mixture of enzymes available for
posttranslational modifications of ICP0 and ICP4 and that host enzymes
can compensate, at least in part, for the absence of appropriate viral
regulatory proteins.
 |
ACKNOWLEDGMENTS |
We thank Charles Van Sant for invaluable advice, Alice P. W. Poon for a careful reading of the manuscript, and Vladimir Mogilner for
photographic services.
These studies were aided by Public Health Service grants CA87761,
CA83939, CA71933, and CA78766 U from the National Cancer Institute.
R.H. is a Howard Hughes Medical Institute predoctoral fellow.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: The Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, 910 E. 58th St., Chicago, IL 60637. Phone: (773) 702-1898. Fax: (773) 702-1631. E-mail: bernard{at}cummings.uchicago.edu.
 |
REFERENCES |
| 1.
|
Ackermann, M.,
D. K. Braun,
L. Pereira, and B. Roizman.
1984.
Characterization of herpes simplex virus 1 alpha proteins 0, 4, and 27 with monoclonal antibodies.
J. Virol.
52:108-118[Abstract/Free Full Text].
|
| 2.
|
Advani, S. J.,
R. Brandimarti,
R. R. Weichselbaum, and B. Roizman.
2000.
The disappearance of cyclins A and B and the increase in activity of the G2/M phase cellular kinase cdc2 in herpes simplex virus 1-infected cells requires the expression of 22/US1.5 and UL13 viral genes.
J. Virol.
74:8-15[Abstract/Free Full Text].
|
| 3.
|
Advani, S. J.,
R. R. Weichselbaum, and B. Roizman.
2000.
The role of cdc2 in the expression of herpes simplex virus genes.
Proc. Natl. Acad. Sci. USA
97:10996-11001[Abstract/Free Full Text].
|
| 4.
|
Blaho, J. A., and B. Roizman.
1991.
ICP4, the major regulatory protein of herpes simplex virus, shares features common to GTP-binding proteins and is adenylated and guanylated.
J. Virol.
65:3759-3769[Abstract/Free Full Text].
|
| 5.
|
Blaho, J. A.,
C. Mitchell, and B. Roizman.
1993.
Guanylylation and adenylylation of the alpha regulatory proteins of herpes simplex virus require a viral beta or gamma function.
J. Virol.
67:3891-3900[Abstract/Free Full Text].
|
| 6.
|
Ehmann, G. L.,
T. I. McLean, and S. L. Bachenheimer.
2001.
Herpes simplex virus type 1 infection imposes a G1/S block in asynchronously growing cells and prevents G1 entry in quiescent cells.
Virology
267:335-349.
|
| 7.
|
Ejercito, P.,
E. D. Kieff, and B. Roizman.
1968.
Characterization of herpes simplex virus strains differing in their effects on social behavior of infected cells.
J. Gen. Virol.
2:357-364[Abstract/Free Full Text].
|
| 8.
|
Everett, R. D., and G. G. Maul.
1994.
HSV-1 IE protein Vmw110 causes redistribution of PML.
EMBO J.
13:5062-5069[Medline].
|
| 9.
|
Everett, R. D.,
M. Meredith,
A. Orr,
A. Cross,
M. Kathoria, and J. Parkinson.
1997.
A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.
EMBO J.
16:566-577[CrossRef][Medline].
|
| 10.
|
Everett, R. D.,
W. C. Earnshaw,
J. Findlay, and P. Lomonte.
1999.
Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.
EMBO J.
18:1526-1538[CrossRef][Medline].
|
| 11.
|
Everett, R. D.
2000.
ICP0 induces the accumulation of colocalizing conjugated ubiquitin.
J. Virol.
74:9994-10005[Abstract/Free Full Text].
|
| 12.
|
Hood, J. K., and P. A. Silver.
1999.
In or out? Regulating nuclear transport.
Curr. Opin. Cell Biol.
11:241-247[CrossRef][Medline].
|
| 13.
|
Jordan, R.,
L. Schang, and P. A. Schaffer.
1999.
Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases.
J. Virol.
73:8843-8847[Abstract/Free Full Text].
|
| 14.
|
Kawaguchi, Y.,
R. Bruni, and B. Roizman.
1997.
Interaction of herpes simplex virus 1 alpha regulatory protein ICP0 with elongation factor 1 : ICP0 affects translational machinery.
J. Virol.
71:1019-1024[Abstract].
|
| 15.
|
Kawaguchi, Y.,
C. Van Sant, and B. Roizman.
1997.
Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3.
J. Virol.
71:7328-7336[Abstract].
|
| 16.
|
Kawaguchi, Y.,
M. Tanaka,
A. Yokoymama,
G. Matsuda,
K. Kato,
H. Kagawa,
K. Hirai, and B. Roizman.
2001.
Herpes simplex virus 1 alpha regulatory protein ICP0 functionally interacts with cellular transcription factor BMAL1.
Proc. Natl. Acad. Sci. USA
98:1877-1882[Abstract/Free Full Text].
|
| 17.
|
King, R. W.,
P. K. Jackson, and M. W. Kirschner.
1994.
Mitosis in transition.
Cell
79:563-571[CrossRef][Medline].
|
| 18.
|
Leopardi, R.,
N. Michael, and B. Roizman.
1995.
Repression of the herpes simplex virus 1 alpha 4 gene by its gene product (ICP4) within the context of the viral genome is conditioned by the distance and stereoaxial alignment of the ICP4 DNA binding site relative to the TATA box.
J. Virol.
69:3042-3048[Abstract].
|
| 19.
|
Lopez, P.,
C. Van Sant, and B. Roizman.
2001.
Requirements for the nuclear-cytoplasmic translocation of infected-cell protein 0 of herpes simplex virus 1.
J. Virol.
75:3832-3840[Abstract/Free Full Text].
|
| 20.
|
Marin, O.,
F. Meggio,
G. Draetta, and L. A. Pinna.
1992.
The consensus sequences for cdc2 kinase and for casein kinase-2 are mutually incompatible. A study with peptides derived from the beta-subunit of casein kinase-2.
FEBS Lett.
301:111-114[CrossRef][Medline].
|
| 21.
|
McLean, T. I., and S. L. Bachenheimer.
1999.
Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication.
J. Virol.
73:8415-8426[Abstract/Free Full Text].
|
| 22.
|
Meijer, L.,
A. Borgne,
O. Mulner,
J. P. Chong,
J. J. Blow,
N. Inagaki,
M. Inagaki,
J. G. Delcros, and J. P. Moulinoux.
1997.
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Eur. J. Biochem.
243:527-536[Medline].
|
| 23.
|
Michael, N.,
D. Spector,
P. Mavromara-Nazos,
T. M. Kristie, and B. Roizman.
1988.
The DNA-binding properties of the major regulatory protein alpha 4 of herpes simplex viruses.
Science
239:1531-1534[Abstract/Free Full Text].
|
| 24.
|
Michael, N., and B. Roizman.
1989.
Binding of the herpes simplex virus major regulatory protein to viral DNA.
Proc. Natl. Acad. Sci. USA
86:9808-9812[Abstract/Free Full Text].
|
| 25.
|
Mitchell, C. A.,
J. A. Blaho,
A. L. McCormick, and B. Roizman.
1997.
The nucleotidylation of herpes simplex virus 1 regulatory protein 22 by human casein kinase II.
J. Biol. Chem.
272:25394-25400[Abstract/Free Full Text].
|
| 26.
|
Ogle, W. O.,
T. I. Ng,
K. L. Carter, and B. Roizman.
1997.
The UL13 protein kinase and the infected cell type are determinants of post-translational processing modifications of ICP0.
Virology
235:406-413[CrossRef][Medline].
|
| 27.
|
Ogle, W. O., and B. Roizman.
1999.
Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US1.5 protein.
J. Virol.
73:4305-4315[Abstract/Free Full Text].
|
| 28.
|
Papavassiliou, A. G.,
K. W. Wilcox, and S. J. Silverstein.
1991.
The interaction of ICP4 with cell/infected-cell factors and its state of phosphorylation modulate differential recognition of leader sequences in herpes simplex virus DNA.
EMBO J.
10:397-406[Medline].
|
| 29.
|
Parkinson, J.,
S. P. Lees-Miller, and R. D. Everett.
1999.
Herpes simplex virus type 1 immediate-early protein Vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase.
J. Virol.
73:650-657[Abstract/Free Full Text].
|
| 30.
|
Post, L. E., and B. Roizman.
1981.
A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth.
Cell
25:227-232[CrossRef][Medline].
|
| 31.
|
Purves, F. C., and B. Roizman.
1992.
The UL13 gene of herpes simplex virus 1 encodes the functions for posttranslational processing associated with phosphorylation of the regulatory protein alpha 22.
Proc. Natl. Acad. Sci. USA
89:7310-7314[Abstract/Free Full Text].
|
| 32.
|
Purves, F. C.,
W. O. Ogle, and B. Roizman.
1993.
Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells.
Proc. Natl. Acad. Sci. USA
90:6701-6705[Abstract/Free Full Text].
|
| 33.
|
Roizman, B., and A. E. Sears.
1996.
Herpes simplex viruses and their replication, p. 2231-2296.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 34.
|
Schang, L. M.,
J. Phillips, and P. A. Schaffer.
1998.
Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
J. Virol.
72:5626-5637[Abstract/Free Full Text].
|
| 35.
|
Schang, L. M.,
A. Rosenberg, and P. A. Schaffer.
1999.
Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
J. Virol.
73:2161-2172[Abstract/Free Full Text].
|
| 36.
|
Schang, L. M.,
A. Rosenberg, and P. A. Schaffer.
2000.
Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
J. Virol.
74:2107-2020[Abstract/Free Full Text].
|
| 37.
|
Sears, A. E.,
I. W. Halliburton,
B. Meignier,
S. Silver, and B. Roizman.
1985.
Herpes simplex virus 1 mutant defective in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice.
J. Virol.
55:338-346[Abstract/Free Full Text].
|
| 38.
|
Van den Heuvel, S., and E. Harlow.
1993.
Distinct roles for cyclin-dependent kinases in cell cycle control.
Science
262:2050-2054[Abstract/Free Full Text].
|
| 39.
|
Van Sant, C.,
Y. Kawaguchi, and B. Roizman.
1999.
A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate.
Proc. Natl. Acad. Sci. USA
96:8184-8189[Abstract/Free Full Text].
|
| 40.
|
Van Sant, C.,
P. Lopez,
S. J. Advani, and B. Roizman.
2001.
Role of cyclin D3 in the biology of herpes simplex virus ICP0.
J. Virol.
75:1888-1898[Abstract/Free Full Text].
|
| 41.
|
Wilcox, K. W.,
A. Kohn,
E. Sklyanaskaya, and B. Roizman.
1980.
Herpes simplex virus phosphoproteins. I. Phosphate cycles on and off some viral polypeptides and can alter their affinity for DNA.
J. Virol.
33:167-182[Abstract/Free Full Text].
|
| 42.
|
Xia, K.,
D. M. Knipe, and N. A. DeLuca.
1996.
Role of protein kinase A and the serine-rich region of herpes simplex virus type 1 ICP4 in viral replication.
J. Virol.
70:1050-1060[Abstract].
|
| 43.
|
Xia, K.,
N. A. DeLuca, and D. M. Knipe.
1996.
Analysis of the phosphorylation sites of herpes simplex virus type 1 ICP4.
J. Virol.
70:1061-1071[Abstract].
|
| 44.
|
Yao, F., and P. A. Schaffer.
1994.
Physical interaction between the herpes simplex virus type 1 immediate-early regulatory proteins ICP0 and ICP4.
J. Virol.
68:8158-8168[Abstract/Free Full Text].
|
| 45.
|
Zhi, Y., and R. M. Sandri-Goldin.
1999.
Analysis of the phosphorylation sites of herpes simplex virus 1 regulatory protein ICP27.
J. Virol.
73:3246-3257[Abstract/Free Full Text].
|
Journal of Virology, September 2001, p. 7904-7912, Vol. 75, No. 17
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.17.7904-7912.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rechter, S., Scott, G. M., Eickhoff, J., Zielke, K., Auerochs, S., Muller, R., Stamminger, T., Rawlinson, W. D., Marschall, M.
(2009). Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity. J. Biol. Chem.
284: 8605-8613
[Abstract]
[Full Text]
-
Boutell, C., Everett, R., Hilliard, J., Schaffer, P., Orr, A., Davido, D.
(2008). Herpes Simplex Virus Type 1 ICP0 Phosphorylation Mutants Impair the E3 Ubiquitin Ligase Activity of ICP0 in a Cell Type-Dependent Manner. J. Virol.
82: 10647-10656
[Abstract]
[Full Text]
-
Yamauchi, Y., Kiriyama, K., Kimura, H., Nishiyama, Y.
(2008). Herpes simplex virus induces extensive modification and dynamic relocalisation of the nuclear mitotic apparatus (NuMA) protein in interphase cells. J. Cell Sci.
121: 2087-2096
[Abstract]
[Full Text]
-
Smith-Donald, B. A., Durand, L. O., Roizman, B.
(2008). Role of Cellular Phosphatase cdc25C in Herpes Simplex Virus 1 Replication. J. Virol.
82: 4527-4532
[Abstract]
[Full Text]
-
Sedlackova, L., Rice, S. A.
(2008). Herpes Simplex Virus Type 1 Immediate-Early Protein ICP27 Is Required for Efficient Incorporation of ICP0 and ICP4 into Virions. J. Virol.
82: 268-277
[Abstract]
[Full Text]
-
Su, Y.-H., Zhang, X., Wang, X., Fraser, N. W., Block, T. M.
(2006). Evidence that the Immediate-Early Gene Product ICP4 Is Necessary for the Genome of the Herpes Simplex Virus Type 1 ICP4 Deletion Mutant Strain d120 To Circularize in Infected Cells. J. Virol.
80: 11589-11597
[Abstract]
[Full Text]
-
Morishige, N., Jester, J. V., Naito, J., Osorio, N., Wahlert, A., Jones, C., Everett, R. D., Wechsler, S. L., Perng, G. C.
(2006). Herpes simplex virus type 1 ICP0 localizes in the stromal layer of infected rabbit corneas and resides predominantly in the cytoplasm and/or perinuclear region of rabbit keratocytes.. J. Gen. Virol.
87: 2817-2825
[Abstract]
[Full Text]
-
Sanchez, V., Spector, D. H.
(2006). Cyclin-Dependent Kinase Activity Is Required for Efficient Expression and Posttranslational Modification of Human Cytomegalovirus Proteins and for Production of Extracellular Particles.. J. Virol.
80: 5886-5896
[Abstract]
[Full Text]
-
Davido, D. J., von Zagorski, W. F., Lane, W. S., Schaffer, P. A.
(2005). Phosphorylation Site Mutations Affect Herpes Simplex Virus Type 1 ICP0 Function. J. Virol.
79: 1232-1243
[Abstract]
[Full Text]
-
Diwan, P., Lacasse, J. J., Schang, L. M.
(2004). Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors. J. Virol.
78: 9352-9365
[Abstract]
[Full Text]
-
Hagglund, R., Roizman, B.
(2004). Role of ICP0 in the Strategy of Conquest of the Host Cell by Herpes Simplex Virus 1. J. Virol.
78: 2169-2178
[Full Text]
-
Davido, D. J., von Zagorski, W. F., Maul, G. G., Schaffer, P. A.
(2003). The Differential Requirement for Cyclin-Dependent Kinase Activities Distinguishes Two Functions of Herpes Simplex Virus Type 1 ICP0. J. Virol.
77: 12603-12616
[Abstract]
[Full Text]
-
Advani, S. J., Durand, L. O., Weichselbaum, R. R., Roizman, B.
(2003). Oct-1 Is Posttranslationally Modified and Exhibits Reduced Capacity To Bind Cognate Sites at Late Times after Infection with Herpes Simplex Virus 1. J. Virol.
77: 11927-11932
[Abstract]
[Full Text]
-
Advani, S. J., Weichselbaum, R. R., Roizman, B.
(2003). Herpes simplex virus 1 activates cdc2 to recruit topoisomerase IIalpha for post-DNA synthesis expression of late genes. Proc. Natl. Acad. Sci. USA
100: 4825-4830
[Abstract]
[Full Text]
-
Schang, L. M.
(2002). Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother
50: 779-792
[Abstract]
[Full Text]
-
Schang, L. M., Bantly, A., Schaffer, P. A.
(2002). Explant-Induced Reactivation of Herpes Simplex Virus Occurs in Neurons Expressing Nuclear cdk2 and cdk4. J. Virol.
76: 7724-7735
[Abstract]
[Full Text]
-
Schang, L. M., Bantly, A., Knockaert, M., Shaheen, F., Meijer, L., Malim, M. H., Gray, N. S., Schaffer, P. A.
(2002). Pharmacological Cyclin-Dependent Kinase Inhibitors Inhibit Replication of Wild-Type and Drug-Resistant Strains of Herpes Simplex Virus and Human Immunodeficiency Virus Type 1 by Targeting Cellular, Not Viral, Proteins. J. Virol.
76: 7874-7882
[Abstract]
[Full Text]
-
Davido, D. J., Leib, D. A., Schaffer, P. A.
(2002). The Cyclin-Dependent Kinase Inhibitor Roscovitine Inhibits the Transactivating Activity and Alters the Posttranslational Modification of Herpes Simplex Virus Type 1 ICP0. J. Virol.
76: 1077-1088
[Abstract]
[Full Text]
-
Advani, S. J., Weichselbaum, R. R., Roizman, B.
(2001). cdc2 Cyclin-Dependent Kinase Binds and Phosphorylates Herpes Simplex Virus 1 UL42 DNA Synthesis Processivity Factor. J. Virol.
75: 10326-10333
[Abstract]
[Full Text]